REGENXBIO Advances Gene Therapy Pipeline with Key 2026 Catalysts
Event summary
- RGX-202 for Duchenne muscular dystrophy shows positive 18-month data, with pivotal topline results expected in early Q2 2026.
- Surabgene lomparvovec (sura-vec) for wet AMD and diabetic retinopathy expects topline data in Q4 2026 and a $100M milestone payment from AbbVie in Q2 2026.
- FDA placed clinical holds on RGX-111 and RGX-121 due to a single case of neoplasm, with REGENXBIO working to address concerns in the CRL.
- Cash position of $240.9M as of December 31, 2025, expected to fund operations into early 2027.
The big picture
REGENXBIO is advancing its late-stage gene therapy pipeline for rare and retinal diseases, with multiple near-term catalysts in 2026. The company's strategic focus on in-house manufacturing and global partnerships aims to deliver curative potential through gene therapy. However, regulatory challenges and financial runway remain critical factors to watch.
What we're watching
- Regulatory Pathway
- Whether REGENXBIO can successfully address the FDA's concerns and resubmit the BLA for RGX-121.
- Clinical Success
- The pace at which RGX-202 and surabgene lomparvovec advance through pivotal trials and deliver topline data.
- Financial Runway
- How long REGENXBIO's current cash position will last and whether additional funding will be required before key milestones.
Related topics